Focinvez is a drug owned by Steriscience Pte Ltd. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 11, 2039. Details of Focinvez's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11065256 | Administration and dosage of diaminophenothiazines |
Jan, 2039
(14 years from now) | Active |
| US11065265 | Compositions of fosaprepitant and methods of preparation |
Jan, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Focinvez's patents.
Latest Legal Activities on Focinvez's Patents
Given below is the list of recent legal activities going on the following patents of Focinvez.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 20 Jul, 2021 | US11065256 |
| Recordation of Patent Grant Mailed | 20 Jul, 2021 | US11065265 |
| Patent Issue Date Used in PTA Calculation | 20 Jul, 2021 | US11065256 |
| Patent Issue Date Used in PTA Calculation | 20 Jul, 2021 | US11065265 |
| Email Notification | 01 Jul, 2021 | US11065265 |
| Email Notification | 01 Jul, 2021 | US11065256 |
| Issue Notification Mailed | 30 Jun, 2021 | US11065265 |
| Issue Notification Mailed | 30 Jun, 2021 | US11065256 |
| Mail Response to 312 Amendment (PTO-271) | 25 Jun, 2021 | US11065256 |
| Email Notification | 25 Jun, 2021 | US11065256 |
US patents provide insights into the exclusivity only within the United States, but Focinvez is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Focinvez's family patents as well as insights into ongoing legal events on those patents.
Focinvez's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Focinvez's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 11, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Focinvez Generics:
Fosaprepitant Dimeglumine is the generic name for the brand Focinvez. 17 different companies have already filed for the generic of Focinvez, with Arthur Grp having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Focinvez's generic
About Focinvez
Focinvez is a drug owned by Steriscience Pte Ltd. Focinvez uses Fosaprepitant Dimeglumine as an active ingredient. Focinvez was launched by Steriscience in 2023.
Market Authorisation Date:
Focinvez was approved by FDA for market use on 22 August, 2023.
Active Ingredient:
Focinvez uses Fosaprepitant Dimeglumine as the active ingredient. Check out other Drugs and Companies using Fosaprepitant Dimeglumine ingredient
Dosage:
Focinvez is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 150MG BASE/50ML (EQ 3MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |